Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA (NI-PMS)

This study has been completed.
Information provided by:
Pfizer Identifier:
First received: February 12, 2009
Last updated: October 21, 2009
Last verified: October 2009
A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.

Condition Intervention Phase
Neuropathic Pain
Drug: Pregabalin
Phase 4

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Assessing the Treatment of Patients With Neuropathic Pain Using LYRICA; A Non Interventional Post-marketing Study (NI-PMS)

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Daily Average Pain Scores [ Time Frame: Baseline, Final Visit (Week 8 or discontinuation) ] [ Designated as safety issue: No ]
  • Pain Related Sleep Interference [ Time Frame: Baseline, Final Visit (Week 8 or discontinuation) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Anxiety and Depression Symptoms [ Time Frame: Baseline, Final Visit (Week 8 or discontinuation) ] [ Designated as safety issue: No ]
  • Clinician Global Improvement of Change (CGIC) at Final Visit (Week 8 or Discontinuation) [ Time Frame: Final Visit (Week 8 or discontinuation) ] [ Designated as safety issue: No ]
  • Patient Global Improvement of Change (PGIC) at Final Visit (Week 8 or Discontinuation) [ Time Frame: Final Visit (Week 8 or discontinuation) ] [ Designated as safety issue: No ]

Enrollment: 691
Study Start Date: September 2006
Study Completion Date: March 2008
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients with neuropathic pain Drug: Pregabalin
Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks

Detailed Description:
A non-interventional study of patients diagnosed with neuropathic pain administered pregabalin and followed up for 8 weeks

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with neuropathic pain

Inclusion Criteria:

  • Clinical diagnosis of neuropathic pain and inclusion according to the current Summary of Product Characteristics.

Exclusion Criteria:

  • The patients were excluded according to the current Summary of Product Characteristics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00843284

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00843284     History of Changes
Other Study ID Numbers: A0081139  ATLAS 
Study First Received: February 12, 2009
Results First Received: March 11, 2009
Last Updated: October 21, 2009
Health Authority: Greece: Ethics Committee

Keywords provided by Pfizer:
neuropathic, pain, pregabalin, Lyrica

Additional relevant MeSH terms:
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Diseases
Peripheral Nervous System Diseases
Signs and Symptoms
Anti-Anxiety Agents
Calcium Channel Blockers
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Tranquilizing Agents processed this record on May 23, 2016